Medscape www.medscape.com

References for:
Pandemic Influenza and Healthcare Demand in the Netherlands: Scenario Analysis

[Emerg Infect Dis 9(5), 2003. © 2003 Centers for Disease Control and Prevention (CDC)]

  1. Yuen KY, Chan PKS, Peiris M, Tsang DNC, Que TL, Shortridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
  2. Claas ECJ, Osterhaus ADME, van Beek R, de Jong JC, Rimmelzwaan GF, Senne DA, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472-7.
  3. Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J Infect Dis 1997;176 (Suppl 1):S4-7.
  4. Belshe RB. Influenza as a zoonosis: how likely is a pandemic?. Lancet 1998;351:460-1.
  5. World Health Organization, Department of Communicable Disease Surveillance and Response. Influenza pandemic plan. The role of the WHO and guidelines for national and regional planning. 1999 Apr. Available from: URL: www.who.int/emc-documents/influenza
  6. Snacken R, Kendal AP, Haaheim LR, Wood JM. The next influenza pandemic: lessons from Hong Kong, 1997. Emerg Infect Dis 1999;5:195-9.
  7. Osterhaus ADME, de Jong JC. The control of influenza: antivirals as an adjunct to vaccines. Vaccine 1999;18:779-80.
  8. Centers for Disease Control and Prevention. Neuraminidase inhibitors for treatment of influenza A and B infections. MMWR Recomm Rep 1999;48:1-9.
  9. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-71.
  10. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002;20:2562-78.
  11. van Genugten MLL, Rutten FFH, Jager JC. Scenario development and costing in health care. Methodological accomplishments and practical guidelines. Utrecht (Netherlands): International Books; 1996.
  12. van Genugten MLL, Heijnen MLA, Jager JC. Scenario analysis of the expected number of hospitalizations and deaths due to pandemic influenza in the Netherlands. Bilthoven (Netherlands): National Institute of Public Health and the Environment; 2002. RIVM report 282701002/2002. Available from: URL: www.rivm.nl/bibliotheek/rapporten/282701002.pdf
  13. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
  14. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000;343:1778-87.
  15. Gross PA, Hermogenes AW, Sacks HS, Lau, JL, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
  16. Postma MJ, Heijnen MLA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in the Netherlands. Pharmacoeconomics 2001;19:215-22.
  17. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
  18. Health Council. Commissie vaccinatie tegen influenza. Vaccinatie bij een griep pandemie. Den Haag: Gezondheidsraad; 2000. Publication no. 2000/1.
  19. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355;827-35.
  20. Hayden FG, Osterhaus ADME, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al. Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337:874-80.
  21. MIST study group. Randomised trial of efficacy and safety of inhaled Zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-81.
  22. Mäkelä MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON, et al. Clinical efficacy and safety of the orally inhaled neuaraminadase inhibitor Zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000;40:42-8.
  23. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016-24.
  24. Nicholson KG, Aoki FY, Osterhaus ADME, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:1845-50.
  25. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410-7.
  26. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33.
  27. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-5.
  28. Murphy KR, Eivindson A, Pauksens K, Stein WJ, Tellier G, Watts R, et al. Efficacy and safety of inhaled Zanamivir for the treatment of influenza in patients with asthma or COPD-a double-blind, randomized, placebo-controlled, multicentre study. Clinical Drug Investigation 2000;20:337-49.
  29. Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high risk patients. Arch Intern Med 2001;161:212-7.
  30. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, et al. Inhaled Zanamivir for the prevention of influenza in families. N Engl J Med 2000;343:1282-9.
  31. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized clinical trial. JAMA 2001;285:748-54.
  32. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor to prevent influenza. N Engl J Med 1999;341:1336-43.
  33. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.
  34. McNichol IR, McNichol JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001;35:57-70.
  35. MacDonald L. New influenza drugs Zanamivir (Relenza) and oseltamivir (Tamiflu): unexpected serious reactions. CMAJ 2000;163:879-81.
  36. Williamson JC. Respiratory distress associated with zanamivir. N Engl J Med 2000;342:661-2.
  37. Cliff AD. Statistical modeling of measles and influenza outbreaks. Stat Methods Med Res 1993;2:43-73.
  38. van Weel C. William Pickles Lecture 1992: what our practices teach us. Br J Gen Pract 1992;42:206-9.
  39. Knottnerus JA, Metsemakers J, Höppener P, Limonard C. Chronic illness in the community and the concept of 'social prevalence'. Fam Pract 1992;9:15-21.
  40. Lamberts H, Hofmans-Okkes I. Episode of care: a core concept in family practice. J Fam Pract 1996;42:161-7.
  41. Bartelds AIM. Continue morbiditeits registration peilstations Nederland 1999. Utrecht (Netherlands): Netherlands Institute of Health Services Research; 2000.
  42. Tacken M, Braspenning J, van Paassen J, van den Hoogen H, de Bakker D, Grol R. Nine years of influenza vaccination in the Netherlands in general practice [in Dutch]. Huisarts Wet 2000;43:566-7.
  43. Vademecum gezondheidsstatistiek, 1999 [in Dutch]. Statistics Netherlands, Heerlen (Netherlands): Voorburg; 1999.
  44. Baltussen RMPM, Reinders A, Sprenger MJW, Postma MJ, Jager JC, Ament AJHA, et al. Estimating influenza related hospitalization in the Netherlands. Epidemiol Infect 1998;121:129-38.
  45. Sprenger MJW, Mulder PGH, Beyer WEP, Strik R van, Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993;22:334-40.